Description
Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH), modified for stability and potency. It is studied for its ability to stimulate endogenous growth hormone release and IGF-1 production, with clinical use in HIV-associated lipodystrophy.
Benefits
- Stimulates natural growth hormone release and IGF-1 production.
- Body composition — studied for reducing visceral adipose tissue (VAT).
- Muscle and strength — explored for supporting lean body mass.
- Metabolic balance — linked to glucose and lipid regulation pathways.
- Anti-aging research — investigated for GH/IGF-1 signaling and recovery benefits.
What researchers look at
- Mechanism: stabilized GHRH analog with extended half-life.
- FDA-approved for HIV-related lipodystrophy due to VAT reduction.
- Increases GH and IGF-1 levels with downstream anabolic effects.
- Preclinical and clinical studies on muscle, metabolism, and recovery.
Quick Specs
- Form: Lyophilized peptide
- Net per vial: 20 mg
- Purity: ≥99% (HPLC)
- Identity: MS-verified (per COA)
- Storage: 2–8 °C, protect from light
Identity Basics
- Type: Synthetic GHRH analog
- Formula / M.W.: C221H366N72O67S, ~5135 g/mol
- CAS: 218949-48-5
Selected Research
- PubChem entry — chemical identity:
https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin
- FDA approval for HIV-associated lipodystrophy:
https://pubmed.ncbi.nlm.nih.gov/21119005/
- VAT reduction and body composition study:
https://pubmed.ncbi.nlm.nih.gov/19779354/
- IGF-1 stimulation and anabolic pathways:
https://pubmed.ncbi.nlm.nih.gov/19574981/
⚠️ Disclaimer
-
This product is intended for laboratory research use only.
-
Not for human or veterinary use.
-
Not approved for diagnostic, therapeutic, or medical applications.
-
Handle using appropriate laboratory safety procedures and personal protective equipment.
